COCP (Cocrystal Pharma) Short Percentage of Float


COCP Cocrystal Pharma Inc COCP
25 GF Score
Price $1.01
! 3 Warning Signs
View Full Analysis

What is Cocrystal Pharma Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

COCP vs OSRH, CVKD, LEXX: Short Percentage of Float Comparison

For the Biotechnology subindustry, Cocrystal Pharma's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cocrystal Pharma Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's Short Percentage of Float falls into.


COCP
25GF Score
Cocrystal Pharma Inc COCP
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cocrystal Pharma Business Description

Other Exchanges 8CC:Germany
Address 19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
25GF Score

Get the complete analysis for COCP

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.01
Price